This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
PLEASANTON, Calif., Jan. 3, 2013 (GLOBE NEWSWIRE) -- ZELTIQ® Aesthetics, Inc. (Nasdaq:ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, announced today that Mark Foley, President and Chief Executive Officer, and Patrick F. Williams, Senior Vice President and Chief Financial Officer, are scheduled to present at the 31
st Annual J.P. Morgan Healthcare Conference.
Event: 31st Annual J.P. Morgan Healthcare Conference
Date: Thursday, January 10, 2013
Time: 3:30 p.m. ET/12:30 p.m. PT
An audio web cast of the Company's presentation will be available by visiting the investor relations section of ZELTIQ's web site at
www.coolsculpting.com. A replay of the presentation will be available for 30 days.
ZELTIQ® Aesthetics, Inc. (Nasdaq:ZLTQ) is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ's first commercial product, the CoolSculpting® System, is designed to selectively reduce stubborn fat bulges that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. CoolSculpting utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer within a treated fat bulge without requiring the patient to diet or exercise.
CONTACT: Patrick F. Williams
ZELTIQ Aesthetics, Inc.
SVP and Chief Financial Officer
Nick Laudico / Amy Glynn
The Ruth Group
646-536-7030 / 7023